• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    3/14/24 5:33:37 PM ET
    $AKBA
    $COEP
    $DHAI
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AKBA alert in real time by email

    Gainers

    • Geron (NASDAQ:GERN) stock increased by 90.8% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $1.8 billion.
    • Madrigal Pharmaceuticals (NASDAQ:MDGL) stock rose 23.16% to $300.0. The market value of their outstanding shares is at $5.9 billion.
    • DIH Holding US (NASDAQ:DHAI) shares rose 10.37% to $1.17. The company's market cap stands at $47.4 million.
    • Synaptogenix (NASDAQ:SNPX) stock increased by 8.33% to $0.2. The company's market cap stands at $3.9 million.
    • Revelation Biosciences (NASDAQ:REVB) shares increased by 8.05% to $2.55. The market value of their outstanding shares is at $1.0 million.
    • Akebia Therapeutics (NASDAQ:AKBA) stock rose 8.02% to $1.48. The market value of their outstanding shares is at $278.7 million. As per the news, the Q4 earnings report came out today.

    Losers

    • Kineta (NASDAQ:KA) stock declined by 8.3% to $0.56 during Thursday's after-market session. The market value of their outstanding shares is at $5.8 million.
    • Trxade Health (NASDAQ:MEDS) shares decreased by 7.38% to $27.0. The market value of their outstanding shares is at $32.5 million.
    • Pieris Pharmaceuticals (NASDAQ:PIRS) stock declined by 6.83% to $0.16. The market value of their outstanding shares is at $15.9 million.
    • Coeptis Therapeutics (NASDAQ:COEP) stock decreased by 6.42% to $0.35. The company's market cap stands at $11.9 million.
    • Nexalin Technology (NASDAQ:NXL) shares declined by 6.28% to $0.51. The market value of their outstanding shares is at $3.6 million.
    • Renovaro (NASDAQ:RENB) stock declined by 6.08% to $2.94. The market value of their outstanding shares is at $422.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKBA
    $COEP
    $DHAI
    $GERN

    CompanyDatePrice TargetRatingAnalyst
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/28/2026$964.00Overweight
    Barclays
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    Madrigal Pharmaceuticals Inc.
    $MDGL
    11/5/2025Neutral → Overweight
    Cantor Fitzgerald
    Madrigal Pharmaceuticals Inc.
    $MDGL
    11/3/2025$445.00Underperform → Neutral
    BofA Securities
    Madrigal Pharmaceuticals Inc.
    $MDGL
    10/15/2025$580.00Buy
    Truist
    Madrigal Pharmaceuticals Inc.
    $MDGL
    9/4/2025$500.00Buy
    H.C. Wainwright
    Geron Corporation
    $GERN
    7/10/2025$1.00Sell
    Goldman
    Akebia Therapeutics Inc.
    $AKBA
    6/4/2025$8.00Buy
    H.C. Wainwright
    More analyst ratings

    $AKBA
    $COEP
    $DHAI
    $GERN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

    CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a virtual R&D Day on Thursday, April 2, 2026 at 10:00 AM EDT. To register for the Akebia virtual R&D Day, click here. The event will feature scientific experts James A. Tumlin, MD (NephroNet), V. Michael Holers, MD (University of Colorado Anschutz) and Jonathan Barratt, MD, PhD, FRCP (University of Leicester) who will join management to discuss Akebia's robust pipeline of clinical stage kidney diseases programs: Praliciguat, a soluble guanylate cyclase stimul

    3/19/26 4:05:00 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

    CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 15, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggre

    3/19/26 4:05:00 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase an aggregate of 956,250 shares of common stock to six newly hired employees as an inducement material to such employees' acceptance of employment with Geron. The stock options have an exercise price of $1.62 per share, which is equal to the closing price of Geron's common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee a

    3/18/26 4:05:00 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $COEP
    $DHAI
    $GERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Butler John P. bought $86,588 worth of shares (69,270 units at $1.25), increasing direct ownership by 2% to 3,367,064 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    3/5/26 6:55:46 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Bros. Advisors Lp bought $36,941,197 worth of shares (97,065 units at $380.58) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    8/20/25 6:12:22 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Bros. Advisors Lp bought $24,979,827 worth of shares (68,618 units at $364.04) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    8/20/25 6:09:53 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $COEP
    $DHAI
    $GERN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    FDA Approval for RYTELO issued to GERON CORP

    Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

    6/7/24 12:36:59 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $COEP
    $DHAI
    $GERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Madrigal Pharmaceuticals with a new price target

    Barclays initiated coverage of Madrigal Pharmaceuticals with a rating of Overweight and set a new price target of $964.00

    1/28/26 7:18:07 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals downgraded by Wolfe Research

    Wolfe Research downgraded Madrigal Pharmaceuticals from Outperform to Peer Perform

    1/6/26 8:41:07 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals upgraded by Cantor Fitzgerald

    Cantor Fitzgerald upgraded Madrigal Pharmaceuticals from Neutral to Overweight

    11/5/25 7:24:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $COEP
    $DHAI
    $GERN
    SEC Filings

    View All

    $AKBA
    $COEP
    $DHAI
    $GERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 10-K filed by Coeptis Therapeutics Holdings Inc.

    10-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    3/19/26 5:00:29 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revelation Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    3/19/26 4:18:58 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

    144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    3/6/26 6:28:13 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CFO Dier Mardi was granted 5,215 shares and sold $853,993 worth of shares (1,982 units at $430.87), increasing direct ownership by 35% to 12,490 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 7:18:32 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Sibold William John was granted 14,995 shares and sold $718,316 worth of shares (1,663 units at $431.94), increasing direct ownership by 9% to 161,829 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 6:49:18 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Kelley Shannon T was granted 4,017 shares and sold $155,498 worth of shares (360 units at $431.94), increasing direct ownership by 43% to 12,138 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 6:34:05 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $COEP
    $DHAI
    $GERN
    Financials

    Live finance-specific insights

    View All

    Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

    Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ake

    2/26/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securities of roughly $401 million Company to host conference call and webcast today, February 25, at 8:00 a.m. ET FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial

    2/25/26 7:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

    CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets. Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A

    2/19/26 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $COEP
    $DHAI
    $GERN
    Leadership Updates

    Live Leadership Updates

    View All

    Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

    SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize Ribo's validated liver targeting siRNA GalSTARTM platform to develop novel treatm

    2/11/26 6:25:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKBA
    $COEP
    $DHAI
    $GERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

    SC 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

    12/17/24 5:42:35 PM ET
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by DIH Holdings US Inc.

    SC 13G/A - DIH HOLDING US, INC. (0001883788) (Subject)

    11/14/24 6:07:49 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 5:46:12 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care